Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Aim(s): To assess the potency of PRRT to render locally advanced or oligometastatic pNENs resectable and to evaluate the effect of surgery after early PRRT on survival.
Materials and methods: A single-center retrospective analysis was performed on 50 pNEN patients, treated between 2000 and 2019 with 177Lu-DOTATATE with a neoadjuvant or downstaging intent. Patients had borderline resectable or unresectable locoregional disease and/or metastatic disease.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.